diabetes

Statins dilemma: heart & cancer benefits, but diabetes risk

/ / 7 Comments
statin_drugs

Statins have been hailed as some of the best drugs ever. Given the massive, deadly prevalence of cardiovascular disease, some have even semi-jokingly talked about putting these drugs in the water supply for public health. The growing evidence (e.g. this story) that statins might significantly aid in prevention, delayed progression, or even post-treatment delay of […]

Statins dilemma: heart & cancer benefits, but diabetes risk Read More »

ViaCyte CEO Laikind Interview: Trial Update, Melton, & Future

/
VC-01-post-implant-final1-e1503703572933, viacyte

It’s been exciting to watch the recent developments in using stem cells as the basis for treatments for Type I Diabetes. One of the major players in this arena is the privately-held company, ViaCyte. In this post, I interview ViaCyte President and CEO, Paul Laikind. The topics include their VC-01 product, the Encaptra device, an update on

ViaCyte CEO Laikind Interview: Trial Update, Melton, & Future Read More »

Diabetes Stem Cell Milestone: ViaCyte Transplants 1st Patient

/ / 4 Comments
viacyte-encaptra

Chalk up another exciting development for the stem cell and regenerative medicine field in 2014 related to diabetes. It’s been a huge year. (Update: read my Fall 2019 interview with ViaCyte here.) For the first time ever, an ES cell-based device has been transplanted into a diabetic patient. ViaCyte working together with Dr. Robert Henry

Diabetes Stem Cell Milestone: ViaCyte Transplants 1st Patient Read More »

The Betatrophin Blues after Harvard Diabetes pub

/ / 9 Comments
Betatrophin

All the recent high-profile papers that are having troubles are bumming me out, with the latest example being the “Betatrophin” Diabetes paper from Harvard last year. Yesterday it was called into major doubt by a new Cell paper from a group led by Jesper Gromada at Regeneron. The authors of the original 2013 Betatrophin paper–Doug Melton’s team at Harvard– indicated

The Betatrophin Blues after Harvard Diabetes pub Read More »

Stem cells for Diabetes: the danger of the word ‘cure’

/ / 3 Comments
Stem-cell-Diabetes-Hype

There has been considerable discussion about the whether the media hyped the recent Harvard stem cells for diabetes paper (see top 10 takeaways of that paper). I believe that this was greatly hyped. This Harvard publication reported production of insulin-secreting cells from human embryonic stem cells (hESC). Newspapers around the world widely exaggerated the potential impact

Stem cells for Diabetes: the danger of the word ‘cure’ Read More »

Takeaways From Harvard Stem Cells for Diabetes Paper

/ / 11 Comments
Harvard-stem-cells-Diabetes

The idea of using stem cells for treat Type I Diabetes is very promising and could have huge practical impact. Real progress has been achieved toward this goal over the last decade. In perhaps another decade there might be a validated treatment. A new stem cell paper has just come out in Cell from Harvard in this

Takeaways From Harvard Stem Cells for Diabetes Paper Read More »

Great News: FDA Nod For ViaCyte IND of Diabetes Stem Cell-Based Product

/ / 8 Comments
ViaCyte-logo-3x2

Type 1 Diabetes is a huge global problem. Where are the solutions that would compliment or replace insulin therapy for diabetics? There haven’t been too many that have gotten very far, which makes the news of a potential stem cell-based therapy moving along in the pipeline all the more exciting. ViaCyte (see more posts here,

Great News: FDA Nod For ViaCyte IND of Diabetes Stem Cell-Based Product Read More »

More on Betatrophin, my take on the Cell paper, and a video

/ / 3 Comments
Melton-Peng-Yi-300x1861

I finally got a chance to read the Cell paper by the Melton team on Betatrophin and it is quite cool. Update — Unfortunately the Betatrophin paper discussed here originally back in 2013 has now largely been proven to have come to incorrect conclusions (for more read this). I think one big question is whether

More on Betatrophin, my take on the Cell paper, and a video Read More »

Clinical Trials Part II: Viacyte Director of Stem Cell Research Dr. D’Amour speaking today in Seattle

/

Viacyte is one of the most exciting biotechs in the stem cells for diabetes space. Dr. Kevin D’Amour, Director of Stem Cell Research at Viacyte, gave an excellent, extremely interesting talk Friday morning: Developing an Encapsulated Stem Cell Therapy for Diabetes. Viacyte talk In the talk, Dr. D’Amour gave a very detailed description of their

Clinical Trials Part II: Viacyte Director of Stem Cell Research Dr. D’Amour speaking today in Seattle Read More »

Subscribe to Our Newsletter

Be the first to know about the latest developments in stem cell and regenerative medicine research.